Bosentan and pulmonary hypertension in patients affected by chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009
Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019
Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 427s Year: 2003
Effect of PDE-5 inhibitor treatment in patients with interstitial lung disease and pulmonary hypertension Source: Annual Congress 2011 - Clinical perspectives in several interstitial diseases Year: 2011
Increased rho-kinase activity is related to pulmonary endothelial dysfunction in patients with chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008
Influence of bronchodilators on pulmonary hypertension (PH) in patients with moderate and severe chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2005; 26: Suppl. 49, 310s Year: 2005
Beta-blockade therapy in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure in the presence and absence of pulmonary hypertension Source: Annual Congress 2010 - COPD: management Year: 2010
Pulmonary hypertension associated with chronic obstructive pulmonary disease Source: Eur Respir J 2006; 28: Suppl. 50, 656s Year: 2006
Effects of amlodipine on pulmonary haemodynamics in pulmonary hypertension (PH) secondary to chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2002; 20: Suppl. 38, 27s Year: 2002
Systemic inflammation in chronic obstructive pulmonary disease in patients with pulmonary hypertension Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities Year: 2010
RESPITE: Riociguat in pulmonary arterial hypertension patients with an inadequate response to phosphodiesterase type 5 inhibitors Source: International Congress 2016 – Clinic of pulmonary hypertension Year: 2016
Platelet characteristics of patients with chronic obstructive pulmonary disease (COPD) accompanied with lung hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 226s Year: 2007
Acute effects of sildenafil in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2008 - Pulmonary hypertension I Year: 2008
Pulmonary arterial hypertension in the patients with chronic obstructive pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 512s Year: 2005
The effect of short-acting beta-two-agonist on pulmonary rehabilitation in chronic obstructive pulmonary disease Source: Annual Congress 2009 - Pulmonary rehabilitation: extending the scope and benefit of rehabilitation for patients with chronic respiratory disease Year: 2009
Enalapril in the management of patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 241s Year: 2003
Effects of Diltiazem on pulmonary hemodynamics and right heart function in patients with chronic obstructive pulmonary disease (COPD)> Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020
Treatment of pulmonary hypertension in chronic obstructive pulmonary disease Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-48-0, page=313 Year: 2006
Pulmonary hypertension in patients with COPD Source: Eur Respir Mon 2012; 57: 138-147 Year: 2012
Impact of exacerbations on pulmonary arterial enlargement in patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013